Document is current

Article History

Received: 11 October 2023

Accepted: 19 March 2024

First Online: 24 May 2024

Declarations

:

: The trial was conducted in accordance with the International Council for Harmonisation Good Clinical Practice guidelines, local regulatory requirements, and the ethical principles of the Declaration of Helsinki. Patients provided written informed consent, and the study protocol was approved by an Institutional Review Board or Independent Ethics Committee at each study site.

: Not applicable.

: VN-C has received grant/research support from AbbVie and Novartis, has acted as a consultant/speaker for, or has received honoraria from, AbbVie, Eli Lilly, Fresenius Kabi, Janssen, MoonLake, MSD, Novartis, Pfizer Inc, and UCB. AD has received grant/research support from AbbVie, Bristol Myers Squibb, Celgene, Eli Lilly, Galvani, Janssen, Novartis, Pfizer Inc, and UCB, has acted as a consultant for AbbVie, Bristol Myers Squibb, Celgene, Eli Lilly, GSK, Janssen, MoonLake, Novartis, Pfizer Inc, and UCB, and has acted as a speaker for, or has received honoraria from, Eli Lilly, Janssen, Novartis, Pfizer Inc, and UCB. RB has received grant/research support from AbbVie, Janssen, Novartis, and Pfizer Inc, has acted as a consultant for AbbVie, Pfizer Inc, and Roche, has acted as a speaker for, or has received honoraria from, AbbVie, Cooper Maroc, Hikma, Janssen, Novartis, Pfizer Inc, Phi, Roche, and Sothema, and has been an advisor or review panel member for AbbVie, Janssen, Hikma, Newbridge, Novartis, Pfizer Inc, Roche, and Sothema. AGB, JCC, and JR are employees and stockholders of Pfizer Inc.